Indian API Market Outlook 2022
India occupies a significant position in global API market. The Indian API industry has been garnering a lot of attention globally due to the good quality of APIs, which are being manufactured in the country. Recently, the Indian API industry has been witnessing a fabulous growth owing to a number of factors. Some of these factors are patent expiry of blockbuster drugs, increasing demand for low costing generics, and innovation of new generation of APIs. Apart from these, rise in geriatric population, increasing disposable income, rising healthcare expenditure, and increasing incidences of chronic diseases are the other reasons which are driving the growth of the Indian API industry.
According to report on “Indian API Market Outlook 2022”, the Indian API domestic consumption market is forecasted to grow at a CAGR of around 10% from FY 2016–FY 2022. This report provides the share of India in the global API market. Furthermore, it gives information about the current scenario of the Indian API market, and future forecasts related to it. RNCOS analysts have mentioned the major drivers of the market, and factors hindering growth of the market.
The Indian API market has been segmented on the basis of various parameters, such as type of manufacturing, type of API, and type of therapeutic area. Moreover, the report highlights the mergers and acquisitions that have taken place in the Indian API market. The regulatory scenario governing the Indian API market along with the various government initiatives for the development of this industry have also been mentioned in the report. Furthermore, the report provides the details about major mergers and acquisitions occurred in the industry.
The last section of the report discusses about the key players in Indian API industry. A brief business overview and financial information about each of these players has been provided in the report. The recent development and strength-weakness analysis of every player has also been presented to assist the investors in developing an understanding of the strategies of major players. In the end, the areas of opportunities and recommendations for the growth of this industry have also been highlighted in the report. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the Indian API market.
According to report on “Indian API Market Outlook 2022”, the Indian API domestic consumption market is forecasted to grow at a CAGR of around 10% from FY 2016–FY 2022. This report provides the share of India in the global API market. Furthermore, it gives information about the current scenario of the Indian API market, and future forecasts related to it. RNCOS analysts have mentioned the major drivers of the market, and factors hindering growth of the market.
The Indian API market has been segmented on the basis of various parameters, such as type of manufacturing, type of API, and type of therapeutic area. Moreover, the report highlights the mergers and acquisitions that have taken place in the Indian API market. The regulatory scenario governing the Indian API market along with the various government initiatives for the development of this industry have also been mentioned in the report. Furthermore, the report provides the details about major mergers and acquisitions occurred in the industry.
The last section of the report discusses about the key players in Indian API industry. A brief business overview and financial information about each of these players has been provided in the report. The recent development and strength-weakness analysis of every player has also been presented to assist the investors in developing an understanding of the strategies of major players. In the end, the areas of opportunities and recommendations for the growth of this industry have also been highlighted in the report. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the Indian API market.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. INDIA API INDUSTRY OUTLOOK
3.1 Share of India in Global API Market
3.2 Indian API Domestic Consumption Market Future Outlook
3.3 Major APIs in the Indian API Market
4. DRIVERS & CHALLENGES
4.1 Drivers
4.1.1 Rising Healthcare Expenditure
4.1.2 Increasing Disposable Incomes
4.1.3 Growing Geriatric Population
4.1.4 Increasing Incidences of Chronic Diseases
4.1.5 Patent Expiry of Blockbuster Drugs
4.1.6 Increased Consumption of Generic Drugs
4.1.7 Invention of New Generation of APIs
4.2 Challenges
4.2.1 Over dependence on China for Imports
4.2.2 Complex License Renewal Procedure
4.2.3 Few Manufacturers in the API Industry
4.2.4 Inadequate Infrastructure Facilities
4.2.5 Lack of Government Support
4.2.6 Stringent Regulatory Policies
5. MARKET SEGMENTATION
5.1 By Type of Manufacturing
5.2 By Type of API
5.3 By Type of Therapeutic Area
6. MERGERS AND ACQUISITIONS
7. GOVERNMENT INITIATIVES
7.1 Katoch Committee
7.2 'Make in India' Campaign
7.3 Pharma Vision 2020
7.4 Establishment of New NIPERs
7.5 Set-Up of Reviewing Committee
7.6 Launch of Fund by Government
8. REGULATORY SCENARIO
9. COMPETITIVE LANDSCAPE
9.1 Sun Pharma
9.2 Cipla Limited
9.3 Biocon
9.4 Dr. Reddy's Laboratories
9.5 Lupin Limited
9.6 Aurobindo Pharma Limited
9.7 Wockhardt
9.8 Zydus Cadila
9.9 Glenmark Pharmaceuticals
9.10 Jubilant LifeSciences
10. OPPORTUNITIES AND RECOMMENDATIONS
10.1 Opportunities
10.2 Recommendations
2. RESEARCH METHODOLOGY
3. INDIA API INDUSTRY OUTLOOK
3.1 Share of India in Global API Market
3.2 Indian API Domestic Consumption Market Future Outlook
3.3 Major APIs in the Indian API Market
4. DRIVERS & CHALLENGES
4.1 Drivers
4.1.1 Rising Healthcare Expenditure
4.1.2 Increasing Disposable Incomes
4.1.3 Growing Geriatric Population
4.1.4 Increasing Incidences of Chronic Diseases
4.1.5 Patent Expiry of Blockbuster Drugs
4.1.6 Increased Consumption of Generic Drugs
4.1.7 Invention of New Generation of APIs
4.2 Challenges
4.2.1 Over dependence on China for Imports
4.2.2 Complex License Renewal Procedure
4.2.3 Few Manufacturers in the API Industry
4.2.4 Inadequate Infrastructure Facilities
4.2.5 Lack of Government Support
4.2.6 Stringent Regulatory Policies
5. MARKET SEGMENTATION
5.1 By Type of Manufacturing
5.2 By Type of API
5.3 By Type of Therapeutic Area
6. MERGERS AND ACQUISITIONS
7. GOVERNMENT INITIATIVES
7.1 Katoch Committee
7.2 'Make in India' Campaign
7.3 Pharma Vision 2020
7.4 Establishment of New NIPERs
7.5 Set-Up of Reviewing Committee
7.6 Launch of Fund by Government
8. REGULATORY SCENARIO
9. COMPETITIVE LANDSCAPE
9.1 Sun Pharma
9.2 Cipla Limited
9.3 Biocon
9.4 Dr. Reddy's Laboratories
9.5 Lupin Limited
9.6 Aurobindo Pharma Limited
9.7 Wockhardt
9.8 Zydus Cadila
9.9 Glenmark Pharmaceuticals
9.10 Jubilant LifeSciences
10. OPPORTUNITIES AND RECOMMENDATIONS
10.1 Opportunities
10.2 Recommendations
LIST OF FIGURES:
Figure 3-1: India API Market Trade (%), FY 2016
Figure 3-2: Share of India in Global API Market (%), FY 2016
Figure 3-3: Indian API Domestic Consumption Market (Billion US$), FY 2016-FY 2022
Figure 4-1: Healthcare Expenditure (US$ per head), 2012-2016
Figure 4-2: Personal Disposable Income (Trillion US$), 2012-2016
Figure 4-3: Indian Population - 60 years or above (Million), 2015 & 2030
Figure 4-4: India - Number of People with Diabetes (Million), 2015 & 2040
Figure 4-5: India - Number of New Cancer Cases (Million), 2015 & 2020
Figure 5-1: Share of Captive and Merchant Market APIs in Indian API Market (%), FY 2016
Figure 5-2: Share of Chemical/Small Molecule and Biotech APIs in Indian API Market (%), FY 2016
Figure 5-3: Share of APIs by their Application in Therapeutic Areas in Indian API Market (%), FY 2016
Figure 8-1: API License Procedure
Figure 3-1: India API Market Trade (%), FY 2016
Figure 3-2: Share of India in Global API Market (%), FY 2016
Figure 3-3: Indian API Domestic Consumption Market (Billion US$), FY 2016-FY 2022
Figure 4-1: Healthcare Expenditure (US$ per head), 2012-2016
Figure 4-2: Personal Disposable Income (Trillion US$), 2012-2016
Figure 4-3: Indian Population - 60 years or above (Million), 2015 & 2030
Figure 4-4: India - Number of People with Diabetes (Million), 2015 & 2040
Figure 4-5: India - Number of New Cancer Cases (Million), 2015 & 2020
Figure 5-1: Share of Captive and Merchant Market APIs in Indian API Market (%), FY 2016
Figure 5-2: Share of Chemical/Small Molecule and Biotech APIs in Indian API Market (%), FY 2016
Figure 5-3: Share of APIs by their Application in Therapeutic Areas in Indian API Market (%), FY 2016
Figure 8-1: API License Procedure
LIST OF TABLES:
Table 3-1: Major APIs in the Indian API Market
Table 4-1: List of Blockbuster Drugs Losing Patent (2016-2022)
Table 4-2: API Import from China (Billion US$), FY 2012 to FY 2015
Table 6-1: Mergers and Acquisitions in Indian Pharmaceutical Industry (2014-2016)
Table 9-1: Sun Pharma - Net Sales (Billion US$), FY 2013, FY 2014 & FY 2015
Table 9-2: Cipla Limited - Total Revenue (Billion US$), FY 2014, FY 2015 & FY 2016
Table 9-3: Biocon - Total Revenue (Billion US$), FY 2014, FY 2015 & FY 2016
Table 9-4: Dr. Reddy's Laboratories - Total Revenue (Billion US$), FY 2014, FY 2015 & FY 2016
Table 9-5: Lupin Limited - Net Sales (Billion US$), FY 2014, FY 2015 & FY 2016
Table 9-6: Aurobindo Pharma Limited - Net Sales (Billion US$), FY 2014, FY 2015 & FY 2016
Table 9-7: Wockhardt - Total Sales (Billion US$), FY 2014, FY 2015 & FY 2016
Table 9-8: Zydus Cadila - Net Sales (Billion US$), FY 2014, FY 2015 & FY 2016
Table 9-9: Glenmark - Net Sales (Billion US$), FY 2014, FY 2015 & FY 2016
Table 9-10: Jubilant LifeSciences - Net Sales (Billion US$), FY 2014, FY 2015 & FY 2016
Table 3-1: Major APIs in the Indian API Market
Table 4-1: List of Blockbuster Drugs Losing Patent (2016-2022)
Table 4-2: API Import from China (Billion US$), FY 2012 to FY 2015
Table 6-1: Mergers and Acquisitions in Indian Pharmaceutical Industry (2014-2016)
Table 9-1: Sun Pharma - Net Sales (Billion US$), FY 2013, FY 2014 & FY 2015
Table 9-2: Cipla Limited - Total Revenue (Billion US$), FY 2014, FY 2015 & FY 2016
Table 9-3: Biocon - Total Revenue (Billion US$), FY 2014, FY 2015 & FY 2016
Table 9-4: Dr. Reddy's Laboratories - Total Revenue (Billion US$), FY 2014, FY 2015 & FY 2016
Table 9-5: Lupin Limited - Net Sales (Billion US$), FY 2014, FY 2015 & FY 2016
Table 9-6: Aurobindo Pharma Limited - Net Sales (Billion US$), FY 2014, FY 2015 & FY 2016
Table 9-7: Wockhardt - Total Sales (Billion US$), FY 2014, FY 2015 & FY 2016
Table 9-8: Zydus Cadila - Net Sales (Billion US$), FY 2014, FY 2015 & FY 2016
Table 9-9: Glenmark - Net Sales (Billion US$), FY 2014, FY 2015 & FY 2016
Table 9-10: Jubilant LifeSciences - Net Sales (Billion US$), FY 2014, FY 2015 & FY 2016
